Table 1

Baseline characteristics by combined GNRI and phosphorus concentration categories

TotalLow-middle GNRIHigh GNRI
(n=6230)Low
phosphorus
(n=342)
Middle
phosphorus
(n=2557)
High
phosphorus
(n=1331)
Low phosphorus
(n=83)
Middle
phosphorus
(n=1070)
High
phosphorus
(n=847)
Age (years)61.1±12.567.4±11.6*64.4±11.759.6±12.460.2±15.059.0±12.255.0±11.8
Male (%)60.859.156.355.971.269.369.6
Dialysis duration (years)5.8
(2.6 to 11.3)
6.6
(2.5 to 11.7)†
5.9
(2.7 to 12.2)
6.8
(3.0 to 12.8)
5
(2.8 to 9.8)
5
(2.0 to 9.5)
5.5
(2.7 to 10.1)
BMI (kg/m2)20.7±3.119.5±2.519.7±2.819.8±3.021.8±2.922.3±2.622.5±2.7
Serum albumin (g/dL)3.8±0.43.5±0.43.6±0.33.7±0.34.2±0.34.1±0.34.2±0.3
Calcium (mg/dL)9.0±0.88.9±0.78.9±0.79.1±0.99.5±0.79.2±0.79.1±0.9
iPTH (pg/mL)133
(53 to 260)
106
(41 to 240)
140
(56 to 262)
120
(54 to 256)
159
(67 to 262)
139
(54 to 252)
131
(50 to 265)
Single-pool Kt/V1.36±0.291.37±0.291.37±0.281.36±0.291.33±0.271.36±0.281.33±0.29
nPNA (g/kg per day)1.04±0.210.93±0.231.01±0.211.11±0.210.94±0.241.02±0.191.10±0.19
Medications (%)
 Phosphate binder81.675.180.279.882.284.986.3
 Oral VDRA46.242.94646.641.150.142.8
 Intravenous VDRA14.25.31315.81113.818.6
Comorbid conditions (%)
 Diabetes mellitus29.738.629.725.33732.628.9
 Hypertension67.968.369.265.976.767.367.2
 Coronary heart disease3037.632.626.235.629.625.5
 Other cardiovascular disease30.139.333.231.332.926.221.2
 Congestive heart failure17.221.518.117.721.915.414.2
 Cerebrovascular disease13.821.516.711.913.711.48.8
 Peripheral vascular disease15.023.116.813.116.413.512.2
 Recurrent cellulitis3.67.3435.52.83.2
 Lung disease2.232.91.92.71.70.9
 Neurological disorder6.713.28.75.39.64.93.2
 Psychiatric disorder3.95.344.44.13.62.9
  • Low-middle GNRI: < highest tertile of GNRI; high GNRI: ≥ highest tertile of GNRI; low phosphorus:<3.5 mg/dL; middle phosphorus: 3.5 to <6.0 mg/dL; high phosphorus: ≥6.0 mg/dL.

  • Mean±SD (all such values).

  • †Median; IQR in parentheses (all such values).

  • BMI, body mass index; GNRI, Geriatric Nutritional Risk Index; iPTH, intact parathyroid hormone; nPNA, normalised protein nitrogen appearance; VDRA, vitamin D receptor activator.